Comparing net survival estimators of XXXX @entity1 .

@entity1 @entity5 @entity204 @entity320 @entity2246
UNASSIGNED: The net survival of a @entity1 diagnosed with a given disease is a quantity often interpreted as the hypothetical survival probability in the absence of causes of @entity204 other than the disease. In a relative survival framework, net survival summarises the excess mortality that @entity1 experience compared with their relevant reference population. Based on follow-up data from the Finnish Cancer Registry, we derived simulation scenarios that describe survival of @entity1 in eight @entity5 sites reflecting different excess mortality patterns in order to compare the performance of the classical Ederer II estimator and the new estimator proposed by Pohar Perme et al. At 5  years, the age-standardised Ederer II estimator performed equally well as the Pohar Perme estimator with the exception of @entity320 in which the Pohar Perme estimator had a smaller @entity2246 ( @entity2246 ). At 10 and 15  years, the age-standardised Ederer II performed most often better than the Pohar Perme estimator. The unstandardised Ederer II estimator had the largest @entity2246 at 5  years. However, its @entity2246 was often superior to those of the other estimators at 10 and 15  years, especially in sparse data. Both the Pohar Perme and the age-standardised Ederer II estimator are valid for 5-year net survival of @entity5 @entity1 . For longer-term net survival, our simulation results support the use of the age-standardised Ederer II estimator. Copyright    2015 John Wiley _ Sons, Ltd.
